New findings suggest allergic responses may protect against skin cancer

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial College London, highlights previously unknown skin defences - and could open avenues for developing new skin cancer treatments.

The early-stage study, published in the journal Nature Immunology, may also provide clues into why allergies are on the rise. Estimates suggest 44 per cent of Britons now suffer from at least one allergy - but the reasons behind the increase are unknown.

The team behind the latest research suggest their findings support the so-called 'Toxin Hypothesis', which proposes that exposure to environmental toxins and chemicals foreign to our body may trigger allergic responses.

The new research focuses on a type of antibody called Immunoglobulin E, or IgE. This protein, which is part of the immune system, triggers allergic reactions by mistakenly recognising a harmless substance - such as peanuts - as a danger. A full-blown attack is launched by the body, under instruction from IgE, resulting in skin rashes, and swelling of face, mouth - and in severe cases - the airway.

However, despite the actions of IgE having such serious consequences in the body, scientists are still puzzled by its original role - and whether it serves any useful purpose.

The latest research suggests the antibody may have a crucial role in defending against the damage caused by environmental chemicals - and thereby protects against cancer. The IgE (triggered by the skin exposure to toxic agents) accumulates at the skin site, and prevents damaged cells from turning into cancerous tumours.

Dr Jessica Strid, lead author of the study from the Department of Medicine at Imperial, explained: "IgE must have some important role in the body - but at the moment scientists are still unclear what it is. We used to think it protects us against parasites - such as intestinal worms - and the lack of worm infections is causing the allergy rise. However, after previous work suggested the body can still fight parasites without IgE, we don't now believe this to be the only purpose.

"Our new work suggests IgE could protect against the damage caused by skin exposure to tumour-promoting chemicals or UV irradiation - and help fight against skin cancer."

In the research, the team found that placing a toxic chemical on mouse skin caused IgE to be induced and travel to the site of damage. Once there, IgE lowered the risk of cancer development in the skin.

They also studied skin tumours from 12 patients with squamous cell carcinoma - the second most common type of skin cancer.

Results showed all tumours, some of which were more aggressive than others, had IgE present. Further analysis of a larger cohort of patients showed that less dangerous or 'low risk' tumours had more IgE-carrying cells, while more serious tumours had less, suggesting IgE may be offering some kind of protective effect against the progression of the cancer.

Dr Strid added: "This is just the beginning of the story - our next step is to find out how exactly IgE may stop skin cells turning cancerous, and to see if we can somehow manipulate the allergic response to either protect against, or treat skin cancer."

She added that the findings also hint that allergies could be linked to chemicals in our modern environment.

"Our work raises a lot of questions - and we now have to set about answering them. But the initial results support the so-called Toxin Hypothesis, which suggests that chemicals in the environment, such as those in air pollution, arising from industrial combustion and car emissions, as well as from tobacco smoke, could damage the skin and cause a rise in IgE. The theory suggests this rise in IgE may play a role in the alarming increase in allergies over the last decades."

She explained IgE may have evolved to kick into action when the skin touched something toxic. "It may be that the IgE would trigger a rash, or a stronger unpleasant response, when the skin contacts something potentially poisonous. This would send a clear message to the body saying this is harmful - don't touch that again."

Crawford G, Hayes MD, Seoane RC, Ward S, Dalessandri T, Lai C, Healy E, Kipling D, Proby C, Moyes C, Green K, Best K, Haniffa M, Botto M, Dunn-Walters D, Strid J.
Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response.
Nat Immunol. 2018 Jul 16. doi: 10.1038/s41590-018-0161-8.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Early functional SARS-COV-2 specific T cell respon…

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not ...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

COVID-19 Vaccine AstraZeneca recommended for use i…

AstraZeneca's COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 c...

Roche announces the upcoming launch of the SARS-Co…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries acceptin...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...

A machine-learning approach to finding treatment o…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes fore...

Bayer to manufacture mRNA vaccine in Germany

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer ...